Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | carboxylesterase | 0.0505 | 1 | 1 |
Mycobacterium tuberculosis | POSSIBLE PARA-NITROBENZYL ESTERASE (FRAGMENT) | 0.0085 | 0 | 0.5 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0505 | 1 | 1 |
Onchocerca volvulus | 0.0085 | 0 | 0.5 | |
Echinococcus multilocularis | acetylcholinesterase | 0.0505 | 1 | 1 |
Brugia malayi | Carboxylesterase family protein | 0.0505 | 1 | 1 |
Echinococcus multilocularis | carboxylesterase 5A | 0.0505 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0505 | 1 | 1 |
Echinococcus granulosus | acetylcholinesterase | 0.0505 | 1 | 1 |
Mycobacterium tuberculosis | POSSIBLE PARA-NITROBENZYL ESTERASE (FRAGMENT) | 0.0085 | 0 | 0.5 |
Echinococcus granulosus | carboxylesterase 5A | 0.0505 | 1 | 1 |
Onchocerca volvulus | 0.0085 | 0 | 0.5 | |
Mycobacterium ulcerans | carboxylesterase, LipT | 0.0085 | 0 | 0.5 |
Mycobacterium tuberculosis | Carboxylesterase LipT | 0.0085 | 0 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.0505 | 1 | 1 |
Trichomonas vaginalis | carboxylesterase domain containing protein, putative | 0.0085 | 0 | 0.5 |
Echinococcus multilocularis | acetylcholinesterase | 0.0505 | 1 | 1 |
Onchocerca volvulus | 0.0085 | 0 | 0.5 | |
Onchocerca volvulus | 0.0085 | 0 | 0.5 | |
Trichomonas vaginalis | spcc417.12 protein, putative | 0.0085 | 0 | 0.5 |
Onchocerca volvulus | 0.0085 | 0 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.0505 | 1 | 1 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0505 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | Antibacterial activity against wild-type Escherichia coli | ChEMBL. | 22560470 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.